Market Place
Sourcing Support
All News #Library
Biotech
TuHURA Biosciences Completes Acquisition of Kineta
30 Jun 2025 //
PR NEWSWIRE
Kineta Updates KVA12123 Phase 1/2 Data at SITC 2024
08 Nov 2024 //
GLOBENEWSWIRE
Kineta Completes Enrollment In VISTA-101 Ph 1 Study For Solid Tumors
08 Oct 2024 //
GLOBENEWSWIRE
KVA12123 Clears Cohorts in Monotherapy in the Phase 1/2 VISTA-101 Trial
12 Mar 2024 //
GLOBENEWSWIRE
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123
22 Feb 2024 //
GLOBENEWSWIRE
Kineta Provides Update on its Phase 1/2 VISTA-101 Clinical Trial of KVA12123
17 Jan 2024 //
GLOBENEWSWIRE
Kineta Publishes Data Demonstrating Potential of Anti-VISTA Antibody KVA12123
13 Dec 2023 //
GLOBENEWSWIRE
Kineta to Host KOL Event to Review Data from VISTA-101 Trial of KVA12123
28 Nov 2023 //
GLOBENEWSWIRE
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123
06 Nov 2023 //
GLOBENEWSWIRE
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody
03 Nov 2023 //
GLOBENEWSWIRE
Kineta Reports Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Trial of KVA12123
17 Oct 2023 //
GLOBENEWSWIRE
Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted
12 Oct 2023 //
GLOBENEWSWIRE
Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
09 Oct 2023 //
GLOBENEWSWIRE
Kineta Announces Positive KVA12123 Monotherapy Safety
03 Oct 2023 //
GLOBENEWSWIRE
Kineta Expands BOD with Biotech Industry Leaders Kim Drapkin & Scott Dylla
28 Jun 2023 //
GLOBENEWSWIRE
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123
12 Apr 2023 //
GLOBENEWSWIRE
Kineta to Host Key Opinion Leader Event on KVA12123
06 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.